BioCryst Pharmaceuticals Inc. (BCRX) Stock Rating Lowered by Zacks Investment Research

BioCryst Pharmaceuticals Inc. (BCRX) Stock Rating Lowered by Zacks Investment Research


According to Zacks, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza.



from Biotech News